摘要
目的:研究乐伐替尼联合PD-1抗体对NSCLC大鼠血清VEGF、免疫功能及生存时间的影响。方法:将50只雄性健康wistar大鼠随机分为5组,每组10只。适应性饲养一周后,模型组、乐伐替尼组、PD-1抗体组、乐伐替尼+PD-1抗体组大鼠接种鼠源Lewis细胞(浓度为10~6)皮下接种10天,构建非小细胞肺癌大鼠模型。乐伐替尼组用药乐伐替尼灌胃(30㎎/㎏),PD-1抗体组静脉注射PD-1抗体,乐伐替尼+PD-1抗体组灌胃(30㎎/㎏,并静脉注射PD-1抗体),正常组和模型组给予同等剂量生理盐水。观察各组大鼠治疗4周后血清VEGF、免疫细胞表达情况,并观察各组大鼠的生存时间。结果:模型组大鼠血清VEGF含量相比正常组增高,经用药治疗后,乐伐替尼组、PD-1抗体组、乐伐替尼+PD-1抗体组VEGF含量均有不同程度下降,且乐伐替尼+PD-1抗体组含量低于乐伐替尼组与PD-1抗体组,差异显著,具有统计学意义;模型组CD3^+、CD4^+、CD4^+/CD8^+、NK细胞含量相比正常组降低,用药治疗后,乐伐替尼组、PD-1抗体组、乐伐替尼+PD-1抗体组CD3^+、CD4^+、CD4^+/CD8^+、NK细胞含量均有不同程度增高,且乐伐替尼+PD-1抗体组含量高于乐伐替尼组与PD-1抗体组,差异显著,具有统计学意义;模型组最早出现死亡个体,且最早全部死亡,与模型组比较,乐伐替尼+PD-1抗体组大鼠的生存时间最长,PD-1抗体组与乐伐替尼组次之,差异显著,具有统计学差异。结论:乐伐替尼联合PD-1抗体可降低非小细胞肺癌大鼠血清VEGF水平,增强免疫功能,延长生存时间。
Objective To study the effect of Sunitinib combined with PD-1 antibody on the expression of serum VEGF immune function and survival time in rats with NSCLC.Methods 50 male healthy Wistar rats were randomly divided into 5 groups,10 rats in each group.After one week of adaptive feeding,rats in model group,Sunitinib group,PD-1 antibody group and Sunitinib+PD-1 antibody group were inoculated with Lewis cells(concentration 10~6)and subcutaneously inoculated for 10 days to construct a rat model of non-small cell lung cancer.The Sunitinib group by intragastric administration of Sunitinib(30 mg/kg),the PD-1 antibody group by injection of PD-1 antibody,the Sunitinib+PD-1 antibody group by intragastric administration of Sunitinib(30 mg/kg,intravenous injection of PD-1 antibody),the normal group and model group were given the same dose of normal saline.The expressions of serum VEGF and immune cells were observed after treatment for 4 weeks in each group,and the survival time of rats in each group.Result The content of serum VEGF in model group was higher than that in normal group,after treatment with drugs,the content of VEGF decreased in different levels in the group Sunitinib,PD-1 antibody and Sunitinib+PD-1 antibody,and the Sunitinib+PD-1 antibody group was lower than that of Sunitinib group and PD-1 antibody group,significant difference was statistically significant;The contents of CD3^+、CD4^+、CD4^+/CD8^+and NK in the model group were lower than that in the normal group,after therapy,the contents of CD3^+、CD4^+、CD4^+/CD8^+,NK cells in different degree in the Sunitinib group,PD-1 antibody group and Sunitinib+PD-1 antibody group,and the Sunitinib+PD-1 antibody group was higher than that of Sunitinib group and PD-1 antibody group,significant difference was statistically significant;The model group first appeared dead individuals,and all died at the earliest,compare with model group,in the Sunitinib+PD-1 antibody group,the survival time was the longest,the Sunitinib group and PD-1 antibody group take second place,significant difference,with statistical difference.Conclusion The combination of Sunitinib and PD-1 can reduce the serum level of VEGF,increase the immune function and prolong the survival time of non small cell lung cancer in rats.
作者
赵惠
房红元
Zhao Hui;Fang Hong-yuan(Shijiazhuang City Luancheng People’s Hospital,Shijiazhuang 051430,China)
出处
《湖南师范大学学报（医学版）》
2020年第2期116-119,共4页
Journal of Hunan Normal University(Medical Sciences)
